Identification of small-molecule inhibitors of the JIP-JNK interaction

Biochemical Journal

Volumn 420, Issue 2, 2009, Pages 283-294

  Chen, Tracy ^a   Kablaoui, Natasha ^a   Little, Jeremy ^a   Timofeevski, Sergel ^a   Tschantz, William R ^b   Chen, Ping ^a   Feng, Junli ^a   Charlton, Maura ^a   Stanton, Robert ^a   Bauer, Paul ^a  

^a PFIZER INC   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

C Jun N terminal kinase (JNK); High throughput screening (HTS); JNK interacting protein (JIP); Polychloropyrimidines; Protein protein interaction; Small molecule inhibitors

Indexed keywords

C-JUN N-TERMINAL KINASE (JNK); HIGH-THROUGHPUT SCREENING (HTS); JNK-INTERACTING PROTEIN (JIP); POLYCHLOROPYRIMIDINES; PROTEIN-PROTEIN INTERACTION; SMALL-MOLECULE INHIBITORS;

AMINES; ELECTRIC BATTERIES; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH TEMPERATURE SUPERCONDUCTORS; INSULIN; MOLECULES;

BINDING SITES;

ADENOSINE TRIPHOSPHATE; BINDING PROTEIN; POLYCHLOROPYRIMIDINE; PYRIMIDINE DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; STRESS ACTIVATED PROTEIN KINASE INTERACTING PROTEIN; UNCLASSIFIED DRUG; ORGANIC COMPOUND; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ANIMAL CELL; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG BINDING SITE; DRUG IDENTIFICATION; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG TARGETING; ENZYME INHIBITION; FLUORESCENCE POLARIZATION; HIGH THROUGHPUT SCREENING; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; HUMAN; METABOLISM; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE;

MUS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; ORGANIC CHEMICALS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 66549126199     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20081899     Document Type: Article

References (39)

1. Chang, L. and Karin, M. (2001) Mammalian MAP kinase signaling cascades. Nature 410, 37-40
2. Adler, V., Polotskaya, A., Wagner, F. and Kraft, A. S. (1992) Affinity-purified c-Jun amino-terminal protein kinase requires serine/ threonine phosphorylation for activity. J. Biol. Chem. 267, 17001-17005
3. Pulverer, B. J., Kyriakis, J. M., Avruch, J., Nikolakaki, E. and Woodgett, J. R. (1991) Phosphorylation of c-Jun mediated by MAP kinases. Nature 353, 670-674
4. Bogoyevitch, M. A., Boehm, I., Oakley, A., Ketterman, A. J. and Barr, R. K. (2004) Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential. Biochim. Biophys. Acta 1697, 89-101
5. Ichijo, H. (1999) From receptors to stress-activated MAP kinases. Oncogene 18, 6087-6093
6. Davis, R. J. (2000) Signal transduction by the JNK group of MAP kinases. Cell 103, 239-252
7. Karin, M. and Gallagher, E. (2005) From JNK to pay dirt: Jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life 57, 283-295
8. Tuncman, G., Hirosumi, J., Solinas, G., Chang, L., Karin, M. and Hotamisligil, G. S. (2006) Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc. Natl. Acad. Sci. U.S.A. 103, 10741-10746
9. Manning, A. M. and Davis, R. J. (2003) Targeting JNK for therapeutic benefit: from Junk to gold? Nat. Rev. Drug Discov. 2, 554-565
10. Bennett, B. L., Satoh, Y. and Lewis, A. J. (2003) JNK: a new therapeutic target for diabetes. Curr. Opin. Pharmacol. 3, 420-425
11. Hirosumi, J., Tuncman, G., Chang, L., Gorgun, C. Z., Uysal, K. T., Maeda, K., Karin, M. and Hotamisligil, G. S. (2002) A central role for JNK in obesity and insulin resistance. Nature 420, 333-336
12. Dickens, M., Rogers, J. S., Cavanagh, J., Raitano, A., Xia, Z., Halpern, J. R., Greenberg, M. E., Sawyers, C. L. and Davis, R. J. (1997) A cytoplasmic inhibitor of the JNK signal transduction pathway. Science 277, 693-696
13. Whitmarsh, A. J. (2006) The JIP family of MAPK scaffold proteins. Biochem. Soc. Trans. 34, 828-832
14. Whitmarsh, A. J., Cavanagh, J., Tournier, C., Yasuda, J. and Davis, R. J. (1998) A mammalian scaffold complex that selectively mediates MAP kinase activation. Science 281, 1671-1674
15. Whitmarsh, A. J., Kuan, C. Y., Kennedy, N. J., Kelkar, N., Haydar, T. F., Mordes, J. P., Appel, M., Rossini, A. A., Jones, S. N., Flavell, R. A. et al. (2001) Requirement of the JIP1 scaffold protein for stress-induced JNK activation. Genes Dev. 15, 2421-2432
16. Barr, R. K., Kendrick, T. S. and Bogoyevitch, M. A. (2002) Identification of the critical features of a small peptide inhibitor of JNK activity. J. Biol. Chem. 277, 10987-10997
17. Heo, Y. S., Kim, S. K., Seo, C. I., Kim, Y. K., Sung, B. J., Lee, H. S., Lee, J. I., Park, S. Y., Kim, J. H., Hwang, K. Y. et al. (2004) Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125. EMBO J. 23, 2185-2195
18. Kaneto, H., Nakatani, Y., Miyatsuka, T., Kawamori, D., Matsuoka, T., Matsuhisa, M., Kajimoto, Y., Ichijo, H., Yamasaki, Y. and Hori, M. (2004) Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat. Med. 10, 1128-1132
19. Arkin, M. R. and Wells, J. A. (2004) Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug Discov. 3, 301-317
20. Cheng, A. C., Coleman, R. G., Smyth, K. T., Cao, Q., Soulard, P., Caffrey, D. R., Salzberg, A. C. and Huang, E. S. (2007) Structure-based maximal affinity model predicts small-molecule druggability. Nat. Biotechnol. 25, 71-75
21. Barr, R. K., Boehm, I., Attwood, P. V., Watt, P. M. and Bogoyevitch, M. A. (2004) The critical features and the mechanism of inhibition of a kinase interaction motif-based peptide inhibitor of JNK. J. Biol. Chem. 279, 36327-36338
22. Stebbins, J. L., De, S. K., Machleidt, T., Becattini, B., Vazquez, J., Kuntzen, C., Chen, L., Cellitti, J. F., Riel-Mehan, M., Emdadi, A. et al. (2008) Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc. Natl. Acad. Sci. U.S.A. 105, 16809-16813
23. Janolino, V. G., Fontecha, J. and Swaisgood, H. E. (1996) A spectrophotometric assay for biotin-binding sites of immobilized avidin. Appl. Biochem. Biotechnol. 56, 1-7
24. Fleming, Y., Armstrong, C. G., Morrice, N., Paterson, A., Goedert, M. and Cohen, P. (2000) Synergistic activation of stress-activated protein kinase 1/c-Jun N-terminal kinase (SAPK1/JNK) isoforms by mitogen-activated protein kinase kinase 4 (MKK4) and MKK7. Biochem. J. 352, 145-154
25. Wasilko, D. J. and Lee, S. E. (2006) TIPS: titerless infected-cells preservation and scale-up. BioProcess. J. 5, 29-32
26. Guenat, S., Rouleau, N., Bielmann, C., Bedard, J., Maurer, F., Allaman-Pillet, N., Nicod, P., Bielefeld-Sevigny, M., Beckmann, J. S., Bonny, C. et al. (2006) Homogeneous and nonradioactive high-throughput screening platform for the characterization of kinase inhibitors in cell lysates. J. Biomol. Screening 11, 1015-1026
27. Davies, S. P., Reddy, H., Caivano, M. and Cohen, P. (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95-105
28. Ember, B. and LoGrasso, P. (2008) Mechanistic characterization for c-Jun-N-terminal kinase 1α1. Arch. Biochem. Biophys. 477, 324-329
29. Cleland, W. W. (1979) Statistical analysis of enzyme kinetic data. Methods Enzymol. 63, 103-138
30. Cha, S. (1975) Tight-binding inhibitors - I. Kinetic behavior. Biochem. Pharmacol. 24, 2177-2185
31. Zhang, J. H., Chung, T. D. and Oldenburg, K. R. (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screening 4, 67-73
32. Lippa, B., Morris, J., Corbett, M., Kwan, T. A., Noe, M. C., Snow, S. L., Gant, T. G., Mangiaracina, M., Coffey, H. A. and Foster, B. (2006) Discovery of novel isothiazole inhibitors of the TrkA kinase: structure-activity relationship, computer modeling, optimization, and identification of highly potent antagonists. Bioorg. Med. Chem. Lett. 16, 3444-3448
33. Niu, L., Chang, K. C., Wilson, S., Tran, P., Zuo, F. and and Swinney, D. C. (2007) Kinetic characterization of human JNK2α2 reaction mechanism using substrate competitive inhibitors. Biochemistry 46, 4775-4784
34. G. D. Searle & Co. (2000) Substituted pyrazoles as p38 kinase inhibitors, Int. Pat. WO/2000/031063
35. Gupta, S., Barrett, T., Whitmarsh, A. J., Cavanagh, J., Sluss, H. K., Derijard, B. and Davis, R. J. (1996) Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 15, 2760-2770
36. Bennett, B. L., Sasaki, D. T., Murray, B. W., O'Leary, E. C., Sakata, S. T., Xu, W., Leisten, J. C., Motiwala, A., Pierce, S., Satoh, Y. et al. (2001) SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. U.S.A. 98, 13681-13686
37. Zhou, T., Sun, L., Humphrey, J. and Goldsmith, E. J. (2006) Docking interactions induce exposure of activation loop in the MAP kinase ERK2. Structure 14, 1011-1019
38. White, A., Pargellis, C. A., Studts, J. M., Werneburg, B. G. and Farmer, II, B. T. (2007) Molecular basis of MAPK-activated protein kinase 2: p38 assembly. Proc. Natl. Acad. Sci. U.S.A. 104, 6353-6358
39. Ember, B., Kamenecka, T. and LoGrasso, P. (2008) Kinetic mechanism and inhibitor characterization for c-Jun-N-terminal kinase 3α1. Biochemistry 47, 3076-3084